Granules India Pursues Strategic M&A to Drive Growth Beyond US and Complex Generics Expansion

Granules India Ltd Embarks on Strategic Shift Towards Complex Formulations and Geographic Diversification

Key Highlights:

• Priyanka Chigurupati, Managing Director of Granules India Ltd, is driving a strategic transformation to diversify the company's revenue streams and reduce dependence on the US market.
• The company aims to expand its presence in Europe, Canada, and Latin America, with a focus on Brazil as a key market.
• Granules plans to move towards higher-margin complex generics, including oncology and peptides, with a goal of launching products in these categories by FY28.

Business Strategy:

Read also: Oshea Herbals Aims for Rs 650 Crore Revenue Amidst Expansion Efforts

• The company will leverage its CDMO business, supported by its Ascelis venture in Switzerland, to offer specialized manufacturing capabilities.
• Granules is open to inorganic growth through M&A to accelerate its transition towards complex formulations.
• The company has completed a Rs 1,762.50 crore capital raise in February 2026 to fund its transition and strengthen its balance sheet.

Revenue Diversification:

• Granules has transformed its business from a conservative, commodity-focused API supplier to a fully integrated finished-dosages player with its own commercial front end in the US.
• The company has expanded its complex-generics portfolio, focusing on Attention Deficit Hyperactivity Disorder (ADHD) and controlled substances, despite market-wide pricing pressures.

Operations and Challenges:

Read also: Suzlon to Expand Business Scope Beyond Wind Energy, Invests Rs 500 Crore in New Subsidiary This Fiscal Year

• Granules relies on its massive scale in legacy "core" molecules, which now account for only 11% of total revenue.
• The company is leveraging its multi-site manufacturing and strategic inventory positioning to manage disruptions caused by the unrest in West Asia.
• The company is working to resolve regulatory issues at its Gagillapur facility in Telangana, which received a USFDA warning letter in 2025.